Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.43 |
| ▸ | SRC | P12931 | 4/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.40 |
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411014 | 0.89 | MAPK14 (0.44) | MAPK14SRCBRAFKDRMAPK10 | |
| SCHEMBL4417405 | 0.85 | MAPK14 (0.47) | MAPK14SRCBRAFKDRMAPK10 | |
| SCHEMBL4415039 | 0.81 | NAMPT (0.43) | MAPK14 | |
| SCHEMBL4411116 | 0.78 | MAPK14 (0.45) | MAPK14SRCBRAFKDRRIPK2 | |
| SCHEMBL4408303 | 0.76 | MAPK14 (0.43) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL2926154 | 0.66 | MAPK14 (0.41) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL4410204 | 0.65 | MAPK14 (0.46) | MAPK14SRCBRAFKDRMAPK10 | |
| SCHEMBL1384557 | 0.64 | MAPK14 (0.46) | MAPK14EGFR | |
| SCHEMBL1385820 | 0.64 | MAPK14 (0.48) | MAPK14SRCBRAFKDREGFR | |
| SCHEMBL2931861 | 0.64 | MAPK14 (0.48) | MAPK14EGFRPTK6MAPK10MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885SRC 391/4885BRAF 108/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | MAPK14 36/4885SRC 391/4885BRAF 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.